bevacizumab
roche
['gyn']
watched on demand 6/5 #asco22 #gyncsm challenges in oc recurrent maintenance options in patients with prior maintenance therapy
parp use in maintenance has improved pfs.
repeat parp benefit is small
evidence supports use of bev 
#ovca survivor; research advocate; author; co-moderator #gyncsm chat;  #ASCO22 Feature Voice  COI: https://t.co/AUF1EprNVt Opinions are my own.